Histological improvement in patients with pegylated interferon alpha-2b plus ribavirin who were previously non-responders to rebetron

Selin, Khaled; Hyun, Christopher; Jensen, Jonathan B.; Rossi, Stephen J.; Lyche, Kip; Weprin, Larry; Oliver, Deanna L.; Myers, Wendy Y.; Ziegler, Beth; Behling, Cynthia; Hassanein, Tarek

doi:10.1016/s0016-5085(03)83543-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical development programs researching the protease inhibitor and polymerase inhibitor drug classes as options in the treatment of HCV nonresponder patients remain in the distant future. Furthermore, retreatment with the same regimen would not be expected to provide benefit, as it has been shown that retreatment of nonresponders to IFN and ribavirin with peg-IFN and ribavirin is effective in only 4-12% of patients [18][19][20][21][22][23]. In a recent study, peg-IFN alfa-2a was shown to produce an SVR rate of only 3% in 34 nonresponders to prior peg-IFN and ribavirin-treated patients [24].…”

Section: Discussionmentioning

confidence: 99%

“…CIFN was reported to produce up to 3 log 10 greater activity than the peg-IFNs [15][16][17]. Retreatment with peg-IFN and ribavirin in nonresponders to IFN or peg-IFN and ribavirin is effective in only 3-12% of patients [18][19][20][21][22][23][24]. In contrast, therapy with CIFN has been effective in 23-30% of the IFN and ribavirin nonresponders [25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Consensus Interferon and Ribavirin in Patients with Chronic Hepatitis C Who Were Nonresponders to Pegylated Interferon alfa-2b and Ribavirin

Leevy

2008

Dig Dis Sci

View full text Add to dashboard Cite

Recent studies suggest that consensus interferon and ribavirin is effective in retreating patients with chronic hepatitis C who failed therapy with interferon alfa and ribavirin. The objective of the present study was to assess the efficacy, safety, and tolerability of consensus interferon and ribavirin in patients who did not respond to pegylated interferon alfa-2b and ribavirin. We retrospectively identified 137 consecutive nonresponders to pegylated interferon alfa-2b and ribavirin and initiated patients on daily treatment with consensus interferon 15 mug subcutaneously and weight-based ribavirin for 48 weeks. If patients were HCV RNA negative at 12 weeks, the dose was reduced to 15 mug three times weekly for the remaining 36 weeks. The sustained virologic response rate was 37%. Daily consensus interferon therapy was safe and well tolerated in all patients. No dose reductions were required, and no patient discontinued therapy. Further studies of consensus interferon and ribavirin in nonresponders are warranted.

show abstract